In univariate analyses, three factors, namely MAP2K1/2 mutations, tumour stage (stage 4 vs stage 3), and the presence of lactate dehydrogenase (LDH; 1 vs 0), were found to be associated with immunotherapeutic OS and PFS (Table 1). This evidence concerns the gene MAP2K1 and neoplasm.